Positive results have been announced from a phase 1 trial evaluating the safety, reactogenicity, and immunogenicity of the rabies vaccine candidate RBI-4000, Replicate Bioscience announced in a release.1 Data from the study, which was previously presented at the 2024 American Society of Gene and Cell Therapy Annual Meeting, was also published in Nature Communications.2
Rabies srRNA Vaccine Demonstrates Robust Immune Response / PEDROMERINO – stock.adobe.com
Data from the study showed a single dose of the RBI-4000 vaccine elicited immune responses in healthy patients, attaining an immune threshold of protection against rabies established by the World Health Organization (WHO) across all dose levels tested. The vaccine candidate was also seen to have good tolerability, with no serious adverse events, dose-limiting…